This invention is a tubular electrospun scaffold of natural protein gelatin and synthetic polyglycolic acid (PGA) / poly-lactic-co-glycolic (PLGA) polymers in a bioreactor system connected to a flow circuit and seeded with cultured fibroblasts and endothelial cells.
The invention consists of new bi-functional protein inhibitors (“BPIs”) for treatment and diagnostics of autoimmune diseases such as MS and experimental autoimmune encephalomyelitis. The novel BPIs are capable of modulating the immune response towards a TH2 response.
This invention relates to a class of devices, the Radar Energy Absorbing Low Draw Vortex Generator (RAD-LDVG), which produce vortices over external or internal aerodynamic and/or hydrodynamic surfaces.
This invention provides an improved method for producing a novel interfacing capillary device that is less costly and more durable than existing sheathless devices. This simplified production method does not require sample dilution, etching, or precision hand tools, and is automated and reproducible.
Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications. These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.
An Aryl Hydrocarbon (AHR) null rat model has been generated with the CRISPR/Cas9 editing system. The rat model may be used to study how exposure to environmental pollutants (especially dioxins), acting through AHR, shapes placental development.